BVS
Bioventus Inc
13.10$
-2.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 30.8% | 33.0% | 33.5% | 39.0% | 38.8% | 37.9% | 36.1% | 38.9% | 40.0% | 39.9% | 38.4% | 38.2% | |
| 3.3% | 4.6% | 3.2% | 4.0% | 5.6% | 5.7% | 3.3% | 4.7% | 6.0% | 7.5% | 5.5% | 4.4% | |
| 3.3% | 4.6% | 3.2% | 4.0% | 5.6% | 5.7% | 3.3% | 4.7% | 6.0% | 7.5% | 5.5% | 4.4% | |
| 13.9% | 15.1% | 15.8% | 17.3% | 15.8% | 17.5% | 17.1% | 18.7% | 18.6% | 18.8% | 18.5% | 20.6% | |
| 12.0% | 11.3% | 12.2% | 11.1% | 11.7% | 12.7% | 13.6% | 13.6% | 13.7% | 12.0% | 12.8% | 11.9% | |
| 0.9% | 0.9% | 0.9% | 0.9% | 1.0% | 1.0% | 1.1% | 1.1% | 1.1% | 1.1% | 1.1% | 1.1% | |
| 60.8% | 59.5% | 59.3% | 53.6% | 53.9% | 55.6% | 57.2% | 54.7% | 53.8% | 53.9% | 55.3% | 52.1% | |
| 72.1% | 72.7% | 72.6% | 76.1% | 75.7% | 74.5% | 73.2% | 71.5% | 70.5% | 66.6% | 64.0% | 58.8% | |
| 19.8% | 21.6% | 21.8% | 29.2% | 27.5% | 28.9% | 25.3% | 26.3% | 23.1% | 23.5% | 22.8% | 22.6% | |
| 2.4% | 3.4% | 4.5% | 4.9% | 5.0% | 3.8% | 5.4% | 6.1% | 1.6% | 2.8% | 2.9% | 3.4% | |
| 2.2% | 2.8% | 2.4% | 3.1% | 2.2% | 3.3% | 2.8% | 3.4% | 3.8% | 1.6% | 3.7% | 3.0% | |
| 46.2% | 45.3% | 44.8% | 43.5% | 44.8% | 42.3% | 44.6% | 42.1% | 44.4% | 40.8% | 38.9% | 34.1% | |
| 21.9% | 21.4% | 21.6% | 19.1% | 19.3% | 20.3% | 21.4% | 22.8% | 23.7% | 26.9% | 29.0% | 33.9% | |
| -38.9% | -39.7% | -41.1% | -44.2% | -46.1% | -48.8% | -52.1% | -49.9% | -49.8% | -49.0% | -51.0% | -44.3% | |
| 7.7% | 7.8% | 8.0% | 8.1% | 8.5% | 9.0% | 9.5% | 9.7% | 9.8% | 10.1% | 10.8% | 10.5% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.